JP2017526683A - 新規なアダマンタン誘導体化合物 - Google Patents
新規なアダマンタン誘導体化合物 Download PDFInfo
- Publication number
- JP2017526683A JP2017526683A JP2017511650A JP2017511650A JP2017526683A JP 2017526683 A JP2017526683 A JP 2017526683A JP 2017511650 A JP2017511650 A JP 2017511650A JP 2017511650 A JP2017511650 A JP 2017511650A JP 2017526683 A JP2017526683 A JP 2017526683A
- Authority
- JP
- Japan
- Prior art keywords
- adamantane
- carboxylic acid
- amide
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 adamantane derivative compounds Chemical class 0.000 title abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 59
- 239000012453 solvate Substances 0.000 claims abstract description 55
- 239000000651 prodrug Substances 0.000 claims abstract description 53
- 229940002612 prodrug Drugs 0.000 claims abstract description 53
- 238000004519 manufacturing process Methods 0.000 claims abstract description 23
- 239000000126 substance Substances 0.000 claims description 72
- 150000001875 compounds Chemical class 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 57
- 230000003779 hair growth Effects 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 150000002367 halogens Chemical class 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 210000002374 sebum Anatomy 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 13
- 230000002280 anti-androgenic effect Effects 0.000 claims description 11
- 230000001737 promoting effect Effects 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 229910004013 NO 2 Inorganic materials 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000011593 sulfur Substances 0.000 claims description 6
- RNNXGANYRSJRHN-UHFFFAOYSA-N 4-(adamantane-1-carbonylamino)-2-methoxybenzoic acid Chemical compound C12(CC3CC(CC(C1)C3)C2)C(=O)NC1=CC(=C(C(=O)O)C=C1)OC RNNXGANYRSJRHN-UHFFFAOYSA-N 0.000 claims description 5
- ONIPPGKVZGHYIM-UHFFFAOYSA-N COC(C=C(C=C1)N)=C1C#N.OC(C1(CC(C2)C3)CC3CC2C1)=O Chemical compound COC(C=C(C=C1)N)=C1C#N.OC(C1(CC(C2)C3)CC3CC2C1)=O ONIPPGKVZGHYIM-UHFFFAOYSA-N 0.000 claims description 5
- VPBSYXAXHLMQIC-UHFFFAOYSA-N N-(1,3-benzoxazol-6-yl)adamantane-1-carboxamide Chemical compound O1C=NC2=C1C=C(C=C2)NC(=O)C12CC3CC(CC(C1)C3)C2 VPBSYXAXHLMQIC-UHFFFAOYSA-N 0.000 claims description 5
- NPGWOPVSESBANY-UHFFFAOYSA-N N-(1-adamantyl)-N-(3-chloro-4-nitrophenyl)acetamide Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(C)=O)C1=CC(=C(C=C1)[N+](=O)[O-])Cl NPGWOPVSESBANY-UHFFFAOYSA-N 0.000 claims description 5
- NONVUYPRDLLELO-UHFFFAOYSA-N N-(1-adamantyl)-N-(3-methoxy-4-nitrophenyl)acetamide Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(C)=O)C1=CC(=C(C=C1)[N+](=O)[O-])OC NONVUYPRDLLELO-UHFFFAOYSA-N 0.000 claims description 5
- VUISLTVILMGLCO-UHFFFAOYSA-N N-(3-chloro-4-nitrophenyl)adamantane-1-carboxamide Chemical compound ClC=1C=C(C=CC=1[N+](=O)[O-])NC(=O)C12CC3CC(CC(C1)C3)C2 VUISLTVILMGLCO-UHFFFAOYSA-N 0.000 claims description 5
- ZFDUZIGSGMUBRE-UHFFFAOYSA-N N-(3-methoxy-4-nitrophenyl)adamantane-1-carboxamide Chemical compound COC=1C=C(C=CC=1[N+](=O)[O-])NC(=O)C12CC3CC(CC(C1)C3)C2 ZFDUZIGSGMUBRE-UHFFFAOYSA-N 0.000 claims description 5
- HSPQGSWBYKREBI-UHFFFAOYSA-N N-(4-bromo-3-methoxyphenyl)adamantane-1-carboxamide Chemical compound BrC1=C(C=C(C=C1)NC(=O)C12CC3CC(CC(C1)C3)C2)OC HSPQGSWBYKREBI-UHFFFAOYSA-N 0.000 claims description 5
- WUKAZOFVBZVCQQ-UHFFFAOYSA-N NC(C=CC(C#N)=C1)=C1Cl.OC(C1(CC(C2)C3)CC3CC2C1)=O Chemical compound NC(C=CC(C#N)=C1)=C1Cl.OC(C1(CC(C2)C3)CC3CC2C1)=O WUKAZOFVBZVCQQ-UHFFFAOYSA-N 0.000 claims description 5
- PDZHTAQPWOJAQQ-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)adamantane-1-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NC1=CC=C(OCO2)C2=C1 PDZHTAQPWOJAQQ-UHFFFAOYSA-N 0.000 claims description 5
- PYUCFBDXEHQVGQ-UHFFFAOYSA-N n-(1,3-benzothiazol-6-yl)adamantane-1-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NC1=CC=C(N=CS2)C2=C1 PYUCFBDXEHQVGQ-UHFFFAOYSA-N 0.000 claims description 5
- VRGZZPKXXOJUPC-UHFFFAOYSA-N n-(2-chloro-4-nitrophenyl)adamantane-1-carboxamide Chemical compound ClC1=CC([N+](=O)[O-])=CC=C1NC(=O)C1(C2)CC(C3)CC2CC3C1 VRGZZPKXXOJUPC-UHFFFAOYSA-N 0.000 claims description 5
- FIRJASDBKRPSOM-UHFFFAOYSA-N n-(2-methoxy-4-nitrophenyl)adamantane-1-carboxamide Chemical compound COC1=CC([N+]([O-])=O)=CC=C1NC(=O)C1(C2)CC(C3)CC2CC3C1 FIRJASDBKRPSOM-UHFFFAOYSA-N 0.000 claims description 5
- BJZSIDFJMNIFIO-UHFFFAOYSA-N n-(3,4-dimethoxyphenyl)adamantane-1-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)C1(C2)CC(C3)CC2CC3C1 BJZSIDFJMNIFIO-UHFFFAOYSA-N 0.000 claims description 5
- TXYQBZUZCLRSAK-UHFFFAOYSA-N n-(3-methoxyphenyl)adamantane-1-carboxamide Chemical compound COC1=CC=CC(NC(=O)C23CC4CC(CC(C4)C2)C3)=C1 TXYQBZUZCLRSAK-UHFFFAOYSA-N 0.000 claims description 5
- YHHAUDLBZJNARU-UHFFFAOYSA-N n-(3-methyl-4-nitrophenyl)adamantane-1-carboxamide Chemical compound C1=C([N+]([O-])=O)C(C)=CC(NC(=O)C23CC4CC(CC(C4)C2)C3)=C1 YHHAUDLBZJNARU-UHFFFAOYSA-N 0.000 claims description 5
- TZDCWSSFXSVSEK-UHFFFAOYSA-N n-(3-nitrophenyl)adamantane-1-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC(NC(=O)C23CC4CC(CC(C4)C2)C3)=C1 TZDCWSSFXSVSEK-UHFFFAOYSA-N 0.000 claims description 5
- DOMQVXNITFPQNL-UHFFFAOYSA-N n-(4-methoxyphenyl)adamantane-1-carboxamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C1(C2)CC(C3)CC2CC3C1 DOMQVXNITFPQNL-UHFFFAOYSA-N 0.000 claims description 5
- HZNJXGKTQVSATD-UHFFFAOYSA-N n-(4-nitrophenyl)adamantane-1-carboxamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1NC(=O)C1(C2)CC(C3)CC2CC3C1 HZNJXGKTQVSATD-UHFFFAOYSA-N 0.000 claims description 5
- ZZPUAFLZMYOTPH-UHFFFAOYSA-N n-phenyladamantane-1-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NC1=CC=CC=C1 ZZPUAFLZMYOTPH-UHFFFAOYSA-N 0.000 claims description 5
- XRBIRJUGUXROIY-UHFFFAOYSA-N n-quinolin-6-yladamantane-1-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)NC1=CC=C(N=CC=C2)C2=C1 XRBIRJUGUXROIY-UHFFFAOYSA-N 0.000 claims description 5
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 150000001448 anilines Chemical class 0.000 claims description 4
- 239000000051 antiandrogen Substances 0.000 claims description 4
- PZIDLTGFCDAOFU-UHFFFAOYSA-N methyl 4-(adamantane-1-carbonylamino)-2-methoxybenzoate Chemical compound COC(C1=C(C=C(C=C1)NC(=O)C12CC3CC(CC(C1)C3)C2)OC)=O PZIDLTGFCDAOFU-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- QEJVSNHATJEZAN-UHFFFAOYSA-N N-(1-adamantyl)-N-(2-chloro-4-nitrophenyl)acetamide Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(C)=O)C1=C(C=C(C=C1)[N+](=O)[O-])Cl QEJVSNHATJEZAN-UHFFFAOYSA-N 0.000 claims description 3
- WEUJABMHGUZWPV-UHFFFAOYSA-N N-(1-adamantyl)-N-(3-methyl-4-nitrophenyl)acetamide Chemical compound C12(CC3CC(CC(C1)C3)C2)N(C(C)=O)C1=CC(=C(C=C1)[N+](=O)[O-])C WEUJABMHGUZWPV-UHFFFAOYSA-N 0.000 claims description 3
- SVKLGAMXPSSPPV-UHFFFAOYSA-N N-(4-fluoro-3-methoxyphenyl)adamantane-1-carboxamide Chemical compound FC1=C(C=C(C=C1)NC(=O)C12CC3CC(CC(C1)C3)C2)OC SVKLGAMXPSSPPV-UHFFFAOYSA-N 0.000 claims description 3
- MOHAYLAHUOYZCC-UHFFFAOYSA-N N-(5,6,7,8-tetrahydronaphthalen-2-yl)adamantane-1-carboxamide Chemical compound C1=C(C=CC=2CCCCC1=2)NC(=O)C12CC3CC(CC(C1)C3)C2 MOHAYLAHUOYZCC-UHFFFAOYSA-N 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 3
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims description 2
- 230000036571 hydration Effects 0.000 claims 2
- 238000006703 hydration reaction Methods 0.000 claims 2
- 239000003098 androgen Substances 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 210000004209 hair Anatomy 0.000 description 48
- 238000005481 NMR spectroscopy Methods 0.000 description 43
- 230000000694 effects Effects 0.000 description 20
- 239000007787 solid Substances 0.000 description 19
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 15
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 14
- 239000002552 dosage form Substances 0.000 description 14
- 201000004384 Alopecia Diseases 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000028327 secretion Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 102000001307 androgen receptors Human genes 0.000 description 11
- 108010080146 androgen receptors Proteins 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 230000003676 hair loss Effects 0.000 description 10
- 208000024963 hair loss Diseases 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 230000002708 enhancing effect Effects 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- XPAYEWBTLKOEDA-UHFFFAOYSA-N 3-methyl-4-nitroaniline Chemical compound CC1=CC(N)=CC=C1[N+]([O-])=O XPAYEWBTLKOEDA-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 230000003658 preventing hair loss Effects 0.000 description 6
- 210000004761 scalp Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- DUEGOHNPUBPUIV-UHFFFAOYSA-N 3-methyl-4-nitrobenzoyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=C1[N+]([O-])=O DUEGOHNPUBPUIV-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 229960003632 minoxidil Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XAACOEWSHBIFGJ-UHFFFAOYSA-N 4-fluoro-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1F XAACOEWSHBIFGJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 3
- 231100000360 alopecia Toxicity 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229960002074 flutamide Drugs 0.000 description 3
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 239000011572 manganese Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical group C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003656 anti-hair-loss Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003646 hair health Effects 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000004036 potassium channel stimulating agent Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 1
- ZJYIRVSPPOOPCL-UHFFFAOYSA-N 1,3-benzoxazol-6-amine Chemical compound NC1=CC=C2N=COC2=C1 ZJYIRVSPPOOPCL-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- LOCWBQIWHWIRGN-UHFFFAOYSA-N 2-chloro-4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1Cl LOCWBQIWHWIRGN-UHFFFAOYSA-N 0.000 description 1
- KTHNITVDTYAHFF-UHFFFAOYSA-N 2-chloro-4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C(Cl)=C1 KTHNITVDTYAHFF-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- GVBHRNIWBGTNQA-UHFFFAOYSA-N 2-methoxy-4-nitroaniline Chemical compound COC1=CC([N+]([O-])=O)=CC=C1N GVBHRNIWBGTNQA-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- KIBJSFKLSFCWSF-UHFFFAOYSA-N 3-(cyclopenten-1-yl)propanoic acid Chemical compound OC(=O)CCC1=CCCC1 KIBJSFKLSFCWSF-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LDSIOPGMLLPSSR-UHFFFAOYSA-N 3-chloro-4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C(Cl)=C1 LDSIOPGMLLPSSR-UHFFFAOYSA-N 0.000 description 1
- WLIWOGMICIAQMC-UHFFFAOYSA-N 3-chloro-4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1Cl WLIWOGMICIAQMC-UHFFFAOYSA-N 0.000 description 1
- JVUHWSGOORVDML-UHFFFAOYSA-N 3-methoxy-4-nitroaniline Chemical compound COC1=CC(N)=CC=C1[N+]([O-])=O JVUHWSGOORVDML-UHFFFAOYSA-N 0.000 description 1
- CCPUOOUROHGAOD-UHFFFAOYSA-N 3-methoxy-4-nitrobenzoyl chloride Chemical compound COC1=CC(C(Cl)=O)=CC=C1[N+]([O-])=O CCPUOOUROHGAOD-UHFFFAOYSA-N 0.000 description 1
- XJCVRTZCHMZPBD-UHFFFAOYSA-N 3-nitroaniline Chemical compound NC1=CC=CC([N+]([O-])=O)=C1 XJCVRTZCHMZPBD-UHFFFAOYSA-N 0.000 description 1
- KTDRJLRJAHBQDQ-UHFFFAOYSA-N 4-amino-2-methoxybenzonitrile Chemical compound COC1=CC(N)=CC=C1C#N KTDRJLRJAHBQDQ-UHFFFAOYSA-N 0.000 description 1
- OREVCMGFYSUYPX-UHFFFAOYSA-N 4-amino-3-chlorobenzonitrile Chemical compound NC1=CC=C(C#N)C=C1Cl OREVCMGFYSUYPX-UHFFFAOYSA-N 0.000 description 1
- RUTNWXBHRAIQSP-UHFFFAOYSA-N 4-bromo-3-methoxyaniline Chemical compound COC1=CC(N)=CC=C1Br RUTNWXBHRAIQSP-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000030695 Sparse hair Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- MIBQYWIOHFTKHD-UHFFFAOYSA-N adamantane-1-carbonyl chloride Chemical compound C1C(C2)CC3CC2CC1(C(=O)Cl)C3 MIBQYWIOHFTKHD-UHFFFAOYSA-N 0.000 description 1
- JIMXXGFJRDUSRO-UHFFFAOYSA-M adamantane-1-carboxylate Chemical compound C1C(C2)CC3CC2CC1(C(=O)[O-])C3 JIMXXGFJRDUSRO-UHFFFAOYSA-M 0.000 description 1
- HMXHTLJHNFKPFN-UHFFFAOYSA-N adamantane;carbonochloridic acid Chemical compound OC(Cl)=O.C1C(C2)CC3CC1CC2C3 HMXHTLJHNFKPFN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 239000003936 androgen receptor antagonist Substances 0.000 description 1
- 230000001548 androgenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- YUPQMVSYNJQULF-UHFFFAOYSA-N methyl 4-amino-2-methoxybenzoate Chemical compound COC(=O)C1=CC=C(N)C=C1OC YUPQMVSYNJQULF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- PTQMMNYJKCSPET-OMHQDGTGSA-N mibolerone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 PTQMMNYJKCSPET-OMHQDGTGSA-N 0.000 description 1
- 229950006489 mibolerone Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- RJSRSRITMWVIQT-UHFFFAOYSA-N quinolin-6-amine Chemical compound N1=CC=CC2=CC(N)=CC=C21 RJSRSRITMWVIQT-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000004563 wettable powder Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
- C07C13/28—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
- C07C13/32—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings
- C07C13/54—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings
- C07C13/605—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system
- C07C13/615—Polycyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with condensed rings with three condensed rings with a bridged ring system with an adamantane ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
- C07C15/02—Monocyclic hydrocarbons
- C07C15/04—Benzene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/58—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C265/00—Derivatives of isocyanic acid
- C07C265/12—Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Abstract
Description
本明細書において、「皮膚」とは、動物の体表を覆う組織を意味し、顔やボディなどの体表を覆う組織だけでなく、頭皮や毛髪を含む最広義の概念である。また、本明細書において、「毛髪」とは、体毛と頭髪を総称し、ヘアー(hair)とも記載されることがある。また、前記毛髪は、人や動物のものをいずれも含む。本明細書において、「育毛」とは、新しい毛髪の生成を促進することだけでなく、既存の毛髪が元気に育つようにすることを意味し、脱毛防止、毛髪成長促進を含む概念である。
[実施例17]アダマンタン-1-カルボン酸(4-フルオロ3-メトキシフェニル)アミド
本発明に係るアダマンタン誘導体が抗アンドロゲン効果を有するかどうかを調べるために、拮抗的ステロイド結合分析法(competitive steroid binding assay)を行って、本発明に係るアダマンタン誘導体が、アンドロゲン受容体(AR、androgen receptor)に対する効能剤のメチルトリエノロン(methyltrienolone)と競合的にアンドロゲン受容体に結合するのかを評価した。
2%のウシ胎児血清が含有されたDMEM(Dulbecco's Modified Eagle's Media)培地で培養したラット由来の毛嚢毛乳頭細胞を96ウェルマイクロタイタープレート(96−well microtiter plate)に1,000細胞/ウェルになるように分注した。陽性対照群としてミノキシジルを10μg/mlの濃度で希釈して添加し、実施例1〜10のアダマンタン誘導体をそれぞれ10μg/mlの濃度で希釈して添加した後、37℃の温度で48時間培養した。培養後、0.2% MTT(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide)溶液を各ウェル当たり50μlずつ添加し、再び37℃の温度で4時間培養した後、生成されたホルマザン(formazane)をDMSO(Dimethylsulfoxide)で溶解させた。マイクロプレートリーダ(microplate reader)を利用して溶解したホルマザンの吸光度を570nmで測定した。測定した吸光度を、単にDMSO溶液だけを処理した対照群の吸光度と比較して得た相対的差から毛乳頭細胞の増殖率(%)を評価し、その結果を下表に表した。
本発明に係るアダマンタン誘導体の毛髪成長促進効果を評価するために、先ず、実施例1〜10のアダマンタン誘導体を、1.0質量%の濃度になるように水/エタノール/1,3-ブチレングリコール(5/3/2)からなる溶媒に溶解させた。生後47〜53日になったマウス(C57BL/6)の背中部位の毛を除去し、背中部位の皮膚がきれいなマウスを選び、各群8匹ずつ選定して、毎日前記1.0質量%のアダマンタン誘導体をマウス当たり150μlずつ21日間塗布した。21日後に新たに生えてきた毛髪の重さを測定して陰性対照群と比較し、その結果を下表に表した。
実施例1〜10のアダマンタン誘導体の皮脂分泌抑制効果を評価するために、次のような実験を行った。皮脂分泌が多いと感じる被験者男女20人を選定し、指定された部位に実施例1〜10を含有する栄養クリーム及び陰性対照群の栄養クリームを4週間毎日塗るようにした。しかる後、皮脂量測定機(Sebumeter SM810、C+K Electronic Co.、ドイツ)を使用して、2週及び4週経過後の平均皮脂減少率(%)を測定し、その結果を下表に表した。
下表に記載された組成により、通常の方法に従って毛髪栄養化粧水を製造する。
下表に記載された組成により、通常の方法に従ってヘアローションを製造する。
下表に記載された組成により、通常の方法に従ってヘアクリームを製造する。
下表に記載された組成により、通常の方法に従って軟膏を製造する。
Claims (14)
- 下記の化学式1で表される化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物であって、
Xは、-NHCO-又は-CONH-であり、
R1とR2は、それぞれ独立して置換され、R1は、水素、ハロゲン、NO2、C1〜C6アルコキシ、CN、CO2Me、CO2H及びNH2からなる群より選ばれ、
R2は、水素、C1〜C6アルコキシ、C1〜C6アルキル、及びハロゲンからなる群より選ばれ、
又は、
R1とR2は互いに連結されヘテロ原子を含んでいてよい環状炭素鎖を形成し、C2−C18シクロアルキル;C4−C18アリール;C2−C18のうちの一つ以上の炭素が窒素、酸素、及び硫黄のうちのいずれか一つ以上のヘテロ原子で置換されたヘテロシクロアルキル;及びC4−C18のうちの一つ以上の炭素が窒素、酸素、及び硫黄のうちのいずれか一つ以上のヘテロ原子で置換されたヘテロアリール;からなる群より選ばれ、
R3は、水素、C1〜C6アルコキシ及びハロゲンからなる群より選ばれる、
前記化学式1で表される化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。 - 前記R2は、水素、C1〜C3アルコキシ、C1〜C3アルキル、及びハロゲンからなる群より選ばれた、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。
- 前記R1とR2は、炭素鎖又はヘテロ原子を含む鎖で連結される、1,3-ジオキソール、1,3-チアゾール、1,3-オキサゾール、ピリジル、及びシクロブチル基からなる群より選ばれる、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。
- 前記ハロゲンはクロリドである、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。
- 前記R1は、NO2又はCNであり、
R2は、水素、メチル、メトキシ又はクロリドであり、
R3は、水素、メトキシ又はクロリドである、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。 - 前記R3が水素でR2がハロゲンである場合、前記R2はクロリドである、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。
- 前記化合物は、
アダマンタン-1-カルボン酸-(3-メチル-4-ニトロフェニル)-アミド;
アダマンタン-1-カルボン酸-(3-メトキシ-4-ニトロフェニル)-アミド;
アダマンタン-1-カルボン酸-(3-クロロ-4-ニトロフェニル)-アミド;
アダマンタン-1-カルボン酸-(2-クロロ-4-ニトロフェニル)-アミド;
アダマンタン-1-カルボキシ酸-(4-シアノ-3-メトキシ-フェニル)-アミド;
アダマンタン-1-カルボキシ酸-(4-シアノ-2-クロロ-フェニル)-アミド;
N-アダマンタン-1-イル-N-(4-ニトロ-3-メチル-フェニル)-アセタミド;
N-アダマンタン-1-イル-N-(4-ニトロ-3-メトキシ-フェニル)-アセタミド;
N-アダマンタン-1-イル-N-(4-ニトロ-3-クロロ-フェニル)-アセタミド;
N-アダマンタン-1-イル-N-(4-ニトロ-2-クロロ-フェニル)-アセタミド;
アダマンタン-1-カルボン酸ベンゾ[1,3]ジオキソール-5-イルアミド;
アダマンタン-1-カルボン酸ベンゾチアゾール-6-イルアミド;
アダマンタン-1-カルボン酸(3-メトキシフェニル)アミド;
アダマンタン-1-カルボン酸(4-ニトロフェニル)アミド;
アダマンタン-1-カルボン酸フェニルアミド;
アダマンタン-1-カルボン酸(3,4-ジメトキシフェニル)アミド;
アダマンタン-1-カルボン酸(4-フルオロ3-メトキシフェニル)アミド;
アダマンタン-1-カルボン酸ベンゾオキサゾール-6-イルアミド;
アダマンタン-1-カルボン酸(4-ブロモ-3-メトキシフェニル)アミド;
アダマンタン-1-カルボン酸キノリン-6-イルアミド;
4-[(アダマンタン-1-カルボニル)-アミノ]-2-メトキシ-安息香酸メチルエステル;
アダマンタン-1-カルボン酸(4-メトキシフェニル)アミド;
アダマンタン-1-カルボン酸(3-ニトロフェニル)アミド;
アダマンタン-1-カルボン酸(5,6,7,8-テトラヒドロナフタレン-2-イル)アミド;
アダマンタン-1-カルボン酸(2-メトキシ-4-ニトロフェニル)アミド;及び
4-[(アダマンタン-1-カルボニル)-アミノ]-2-メトキシ安息香酸からなる群より選ばれる、請求項1に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物。 - 請求項1〜7のいずれか一項に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物を含む組成物。
- 前記組成物は皮膚外用剤である、請求項8に記載の組成物。
- 前記組成物は抗アンドロゲン用である、請求項8に記載の組成物。
- 前記組成物は育毛促進用である、請求項8に記載の組成物。
- 前記組成物は皮脂抑制用である、請求項8に記載の組成物。
- 前記組成物は、組成物の全質量を基準にして、請求項1〜6のいずれか一項に記載の化合物、その異性体、その薬学的に許容可能な塩、そのプロドラッグ、その水和物又はその溶媒和物を0.01質量%〜20質量%の範囲で含む、請求項8に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0113975 | 2014-08-29 | ||
KR20140113975 | 2014-08-29 | ||
KR10-2015-0108849 | 2015-07-31 | ||
KR1020150108849A KR102529578B1 (ko) | 2014-08-29 | 2015-07-31 | 신규 아다만탄 유도체 화합물 |
PCT/KR2015/008816 WO2016032182A1 (ko) | 2014-08-29 | 2015-08-24 | 신규 아다만탄 유도체 화합물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017526683A true JP2017526683A (ja) | 2017-09-14 |
JP6594957B2 JP6594957B2 (ja) | 2019-10-23 |
Family
ID=55536985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017511650A Active JP6594957B2 (ja) | 2014-08-29 | 2015-08-24 | 新規なアダマンタン誘導体化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10696611B2 (ja) |
EP (1) | EP3187486B1 (ja) |
JP (1) | JP6594957B2 (ja) |
KR (1) | KR102529578B1 (ja) |
CN (1) | CN107207416B (ja) |
TW (1) | TWI676612B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019176173A (ja) * | 2014-12-09 | 2019-10-10 | サイマー リミテッド ライアビリティ カンパニー | 光源内の外乱の補償 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102635194B1 (ko) | 2018-05-14 | 2024-02-13 | (주)아모레퍼시픽 | 다이아릴 유도체 화합물 및 그를 포함하는 피부 미백용 조성물 |
RU2698193C1 (ru) * | 2019-02-07 | 2019-08-23 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ) | Способ получения ароматических амидов 1-адамантанкарбоновой кислоты |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4857939A (ja) * | 1971-11-15 | 1973-08-14 | ||
JPS50100001A (ja) * | 1972-06-27 | 1975-08-08 | ||
JP2001524468A (ja) * | 1997-11-21 | 2001-12-04 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト |
US6348625B1 (en) * | 2000-11-10 | 2002-02-19 | Gloria Long Anderson | Method for preparing some 1-adamantancecarboxamides |
JP2003500480A (ja) * | 1999-06-02 | 2003-01-07 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 代謝型グルタミン酸受容体アンタゴニストおよび中枢神経系の疾病を治療するためのその使用 |
JP2006522744A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
JP2007503430A (ja) * | 2003-08-26 | 2007-02-22 | アモレパシフィック コーポレーション | ヒドロキサム酸誘導体及びその製造方法 |
US20080027049A1 (en) * | 2006-07-27 | 2008-01-31 | Wyeth | Benzofurans as potassium ion channel modulators |
JP2008536818A (ja) * | 2005-03-24 | 2008-09-11 | ステリックス リミテッド | 11−βヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
WO2009035997A2 (en) * | 2007-09-14 | 2009-03-19 | Cara Therapeutics, Inc. | Benzo-fused heterocycles |
JP2011524391A (ja) * | 2008-06-17 | 2011-09-01 | インスティチュート・パスツール・コリア | 抗結核剤としてのピリドピリミジン化合物 |
JP2013505942A (ja) * | 2009-09-23 | 2013-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレート | Toll様受容体モジュレーター及びその使用 |
KR20130037405A (ko) * | 2011-10-06 | 2013-04-16 | (주)아모레퍼시픽 | 신규 아다만탄 유도체 화합물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3944675A (en) * | 1973-03-15 | 1976-03-16 | Schering Corporation | Substituted aryl and aralkyl amides in the treatment of parkinsonism |
SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
US7220532B2 (en) * | 2002-09-12 | 2007-05-22 | Sumitomo Chemical Company, Limited | Chemical amplification type resist composition |
JP5550041B2 (ja) | 2007-09-27 | 2014-07-16 | 塩野義製薬株式会社 | チトクロームp450を用いたアダマンタン水酸化体の製造方法 |
KR100858224B1 (ko) | 2008-06-24 | 2008-09-10 | 동아제약주식회사 | 도두 추출물을 함유하는 탈모방지 및 모발 성장촉진 효과를 갖는 모발용 화장료 조성물 |
KR20110064989A (ko) | 2009-12-09 | 2011-06-15 | 경북대학교 산학협력단 | 알파-리포익산을 포함하는 탈모예방 또는 치료용 조성물 |
-
2015
- 2015-07-31 KR KR1020150108849A patent/KR102529578B1/ko active IP Right Grant
- 2015-08-24 CN CN201580055458.XA patent/CN107207416B/zh active Active
- 2015-08-24 US US15/506,972 patent/US10696611B2/en active Active
- 2015-08-24 JP JP2017511650A patent/JP6594957B2/ja active Active
- 2015-08-24 EP EP15835660.0A patent/EP3187486B1/en active Active
- 2015-08-28 TW TW104128312A patent/TWI676612B/zh not_active IP Right Cessation
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4857939A (ja) * | 1971-11-15 | 1973-08-14 | ||
JPS50100001A (ja) * | 1972-06-27 | 1975-08-08 | ||
JP2001524468A (ja) * | 1997-11-21 | 2001-12-04 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 中枢神経系疾患を治療するための代謝調節型グルタミン酸受容体アンタゴニスト |
JP2003500480A (ja) * | 1999-06-02 | 2003-01-07 | エヌピーエス ファーマシューティカルズ インコーポレーテッド | 代謝型グルタミン酸受容体アンタゴニストおよび中枢神経系の疾病を治療するためのその使用 |
US6348625B1 (en) * | 2000-11-10 | 2002-02-19 | Gloria Long Anderson | Method for preparing some 1-adamantancecarboxamides |
JP2006522744A (ja) * | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、11β−ヒドロキシステロイドデヒドロゲナーゼ1型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
JP2007503430A (ja) * | 2003-08-26 | 2007-02-22 | アモレパシフィック コーポレーション | ヒドロキサム酸誘導体及びその製造方法 |
JP2008536818A (ja) * | 2005-03-24 | 2008-09-11 | ステリックス リミテッド | 11−βヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
US20080027049A1 (en) * | 2006-07-27 | 2008-01-31 | Wyeth | Benzofurans as potassium ion channel modulators |
WO2009035997A2 (en) * | 2007-09-14 | 2009-03-19 | Cara Therapeutics, Inc. | Benzo-fused heterocycles |
JP2011524391A (ja) * | 2008-06-17 | 2011-09-01 | インスティチュート・パスツール・コリア | 抗結核剤としてのピリドピリミジン化合物 |
JP2013505942A (ja) * | 2009-09-23 | 2013-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレート | Toll様受容体モジュレーター及びその使用 |
KR20130037405A (ko) * | 2011-10-06 | 2013-04-16 | (주)아모레퍼시픽 | 신규 아다만탄 유도체 화합물 |
Non-Patent Citations (17)
Title |
---|
ACS CHEMICAL BIOLOGY, vol. 7, no. 8, JPN6019009944, 2012, pages 1377 - 1384, ISSN: 0004055010 * |
BAEK, HEUNG SOO ET AL.: "The inhibitory effect of new hydroxamic acid derivatives on melanogenesis", BULLETIN OF THE KOREAN CHEMICAL SOCIETY, vol. 29(1), JPN6019009952, 2008, pages 43 - 46, ISSN: 0004055019 * |
BENEDI, CAROLINA ET AL.: "Synthesis of 2-substituted-benzothiazoles by palladium-catalyzed intramolecular cyclization of o-bro", TETRAHEDRON LETTERS, vol. 44(32), JPN6019009969, 2003, pages 6073 - 6077, ISSN: 0004055020 * |
DATABASE REGISTRY [ONLINE], vol. Retrieved from STN, JPN7019001934, 4 August 2003 (2003-08-04), pages <URL:https://stnweb-japan.cas.org/>, ISSN: 0004055006 * |
DATABASE REGISTRY [ONLINE], vol. Retrieved from STN, JPN7019001935, 16 October 2002 (2002-10-16), pages <URL:https://stnweb-japan.cas.org/>, ISSN: 0004055007 * |
DATABASE REGISTRY [ONLINE], vol. Retrieved from STN, JPN7019001936, 23 June 2003 (2003-06-23), pages <URL:https://stnweb-japan.cas.org/>, ISSN: 0004055008 * |
DIKUSAR, E. A. ET AL.: "Synthesis of New 1-Adamantanecarboxylic Acid Derivatives", RUSSIAN JOURNAL OF ORGANIC CHEMISTRY (TRANSLATION OF ZHURNAL ORGANICHESKOI KHIMII), vol. 40(3), JPN6019009955, 2004, pages 346 - 352, ISSN: 0004055021 * |
DORNBUSH, PADRAICK J. ET AL.: "Preliminary studies of 3,4-dichloroaniline amides as antiparasitic agents: Structure-activity analys", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20(17), JPN6019009954, 2010, pages 5299 - 5301, ISSN: 0004055016 * |
FIROUZABADI, HABIB ET AL.: "Dodecatungstophosphoric acid (H3PW12O40) as a highly efficient catalyst for the amidation of alcohol", CATALYSIS COMMUNICATIONS, vol. 9(4), JPN6019009964, 2008, pages 529 - 531, ISSN: 0004055011 * |
HUI, XU ET AL.: "Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 16(4), JPN6019009960, 2006, pages 815 - 820, ISSN: 0004055017 * |
KIM, HYUNWOO ET AL.: "Iridium-Catalyzed C-H Amination with Anilines at Room Temperature: Compatibility of Iridacycles with", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 136(16), JPN6019009966, 2014, pages 5904 - 5907, ISSN: 0004055012 * |
KREUTZBERGER, ALFRED ET AL.: "Potential virus inhibitors, N-[1-adamantyl]carboxylic acid amides", TETRAHEDRON LETTERS, vol. 52, JPN6019009945, 1970, pages 4523 - 4526, ISSN: 0004055009 * |
RAPOLU, RAJESH KUMAR ET AL.: "Silica sulfuric acid: a reusable solid catalyst for the synthesis of N-substituted amides via the Ri", RSC ADVANCES, vol. 3(16), JPN6019009948, 2013, pages 5332 - 5337, ISSN: 0004055013 * |
RENSLO, ADAM R. ET AL.: "Synthesis and Assembly of Self-Complementary Cavitands", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 122(19), JPN6019009950, 2000, pages 4573 - 4582, ISSN: 0004055015 * |
SHOKOVA, ELVIRA ET AL.: "Adamantylation and adamantylalkylation of amides, nitriles and ureas in trifluoroacetic acid", SYNTHESIS, vol. 9, JPN6019009967, 1997, pages 1034 - 1040, XP002353955, ISSN: 0004055014 * |
SU, XIANGDONG ET AL.: "Discovery of novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 301(1-2), JPN6019009958, 2009, pages 169 - 173, ISSN: 0004055022 * |
WAGNER, G. ET AL.: "Covalent binding of 1-aminoadamantane derivatives to protein antigens using isothiocyanate and imidi", PHARMAZIE, vol. 36(6), JPN6019009947, 1981, pages 400 - 402, ISSN: 0004055018 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019176173A (ja) * | 2014-12-09 | 2019-10-10 | サイマー リミテッド ライアビリティ カンパニー | 光源内の外乱の補償 |
Also Published As
Publication number | Publication date |
---|---|
KR20160026678A (ko) | 2016-03-09 |
TW201615617A (zh) | 2016-05-01 |
JP6594957B2 (ja) | 2019-10-23 |
KR102529578B1 (ko) | 2023-05-09 |
TWI676612B (zh) | 2019-11-11 |
CN107207416B (zh) | 2020-02-07 |
EP3187486A1 (en) | 2017-07-05 |
CN107207416A (zh) | 2017-09-26 |
EP3187486B1 (en) | 2023-10-18 |
US20170283347A1 (en) | 2017-10-05 |
EP3187486A4 (en) | 2018-05-02 |
US10696611B2 (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1119557B1 (de) | Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel | |
JP3073047B2 (ja) | 毛髪の脱落防止並びに発育促進用組成物 | |
EP1399423B9 (de) | Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe | |
FR2651122A1 (fr) | Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3. | |
DE10059418A1 (de) | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen | |
EP1261593B1 (de) | 8,8a-dihydro-indeno 1,2-d]thiazol-derivate, die in 2-stellung einen substituenten mit einer sulfonamidstruktur oder sulfonstruktur tragen; verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
EP1259498B1 (de) | 8,8a-dihydro-indeno [1,2-d]thiazol-derivate, die in 8a-stellung substituiert sind, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel z.b. als anorektika | |
EP1341764A1 (de) | Ortho-substituierte stickstoffhaltige bisarylverbindungen zur verwendung als kalium-kanal-inhibitoren | |
EP1349846A1 (de) | Arylierte furan- und thiophencarbonsaureamide mit kalium kanal blockierender wirkung | |
JP6594957B2 (ja) | 新規なアダマンタン誘導体化合物 | |
JP2007521328A (ja) | アンドロゲン受容体モジュレーター | |
EP1230230A1 (de) | Indeno-, naphtho- und benzocyclohepta-dihydrothiazol derivate, deren herstellung und deren verwendung als anorektische arzneimittel | |
EP3786156A1 (en) | 10h-phenothiazine ferroptosis inhibitor and preparation method therefor and application thereof | |
EP1098891A1 (de) | Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
KR101957843B1 (ko) | 신규 아다만탄 유도체 화합물 | |
DE60317632T2 (de) | 2-oxazolamine und ihre verwendung als 5-ht2b-rezeptor-antagonisten | |
FR2677247A1 (fr) | Composition pour freiner la chute des cheveux et pour induire et stimuler leur croissance, a base de derives de pyridine-1 oxyde. | |
KR101693034B1 (ko) | 카페익산 유도체를 유효성분으로 포함하는 피부미백 조성물 | |
EP0212107A1 (de) | 1,4-Dihydro-5-sulfamoyl-nicotinsäureester | |
CA2064910A1 (fr) | Derives de diamino-2,4 triazine 1,3,5 et leur utilisation pour le traitement et la prevention de la chute des cheveux | |
WO2001062745A1 (de) | SUBSTITUIERTE 8,8a-DIHYDRO-3aH-INDENO[1,2-d]THIAZOLE, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL | |
JPH10109968A (ja) | ジメチルプロパンジオール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180626 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190313 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190326 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190809 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190827 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190925 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6594957 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |